Inotek's Recent PARP Publications

2005

Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo F, Szabo C, Li H, Salzman AL, Dolan ME, Modrich P, Bigner DD, Friedman HS. 2005.  Poly (ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair -deficit malignant glioma xenograft.  Mol Cancer Ther.  4(9): 1364-8.

Jagtap P,  Szabó C. 2005.  Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors.  Nature Reviews Drug Discovery. 4(5): 421-440.

Jagtap PG,  Baloglu E, Southan GJ, Mabley JG, Li H,  Zhou J, van Duzer J, Salzman AL, and  Szabó C.  2005.  Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone.  Journal of Medicinal Chemistry. 48(16):  5100-5103.

Komjati K, Besson VC, and Szabo C.  2005. Poly (ADP-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.  Curr Drug Targets CNS Neurol Disord. 4(2): 179-94.

Mabley JG, Hovarth EM, Murthy KG, Zsengeller Z, Vaslin A, Benko R, Kollai M, and Szabo C. 2005.  Gender differences in the endotoxin-induced inflammatory and vascular repsonses: potential role of poly (ADP-ribose) polymerase activation.  J. Pharmacol Exp Ther 315(2): 812-20.

Szabo, C.  2005. Cardioprotective effects of poly(ADP-ribose) polymerase inhibition.  Pharmacol Res. 52(1): 34-43.

Szabo, C.  2005. Roles of poly (ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.  Pharmacol Res. 52(1):  60-71.

Szabo, C. 2005.  Pharmacological inhibition of poly (ADP-ribose) polymerase in cardiovascular disorders: future directions.  Curr Vasc Pharmacol. 3(3): 301-3.

Xiao CY, Chen M, Zsengeller Z, Li H, Kiss L, Kollai M, Szabo C. 2005.  Poly (ADP-ribose) polymerase promotes cardiac remodeling contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure.  J Pharmacolo Exp Ther. 312(3):  891-8.

2004

Benko R, Pacher P, Vaslin A, Kollai M, Szabo C.  2004.  Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly (ADP-ribose) polymerase.  Life Sciences 75: 1255-1261.

Brock W, Milas L, Bergh S, Lo R, Szabo C, Mason K. 2004. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Letters 205: 155-160

Chen M, Zsengeller Z, Xiao C, Szabo C. 2004.  Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly (ADP-ribose) polymerase-1. Cardiovascular Research (63) 682-688.

Farivar A, Woolley S, Frag C, Thomas R, Salzman A, Szabo C, Mulligan M. 2004. Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury. Ann Thorac Surg 7:1938-43

Farivar A, Woolley S, Naidu B, Fraga C, Byrne K, Thomas R, Salzman A, Szabo C, Mulligan M. 2004.  Poly (ADP) ribose synthetase inhibition reduces obliterative airway disease in rat tracheal allografts. J Heart Lung Transplant 23:993-1002.

Jagtap P, Southan G,  Baloglu E,  Ram S,  Mabley J,  Marton A,  Salzman A, Szabo C. 2004. The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones:potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg.Med.Chem.Lett.14:81-85

Komjati K,  Mabley J, Virag L, Southan G, Salzman A, Szabo C. 2004. Poly (ADP-ribose) polymerase inhibition protects neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int J Mol Med. 13(3):373-82.

Li F, Szabo C, Pacher P, Southan G, Abatan O, Charniauskaya T, Stevens M, Obrosova I.  2004.  Evaluation of orally active poly (ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 47:710-717

Mabley J, Pacher P, Bai P, Wallace R, Goonesekera S, Virag L, Southan G, Szabo C.  2004. Suppression of intestinal polyposis in Apc-/+ mice by targeting the nitric oxide or poly (ADP-ribose) pathways. Mutation Research 107-116.

Murakami K, Enkhbaater P, Shimoda K, Cox R, Burke A, Hawkins H, Traber L, Schmalstieg F, Salzman A, Mabley J, Komjati K, Pacher P, Zsengeller Z, Szabo C, Traber D.  2004.  Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock 21(2):126-133.

Murthy K,  Szabo C,  Salzman A. 2004. Cytokines stimulate expression of inducible nitric oxide synthase in DLD-1 human adenocarcinoma cells by activating poly(A) polymerase. Inflamm. Res  53:604-608.

Obrosova I, Minchenko A, Frank R, Seigel G, Zsengeller Z, Pacher P, Stevens M, Szabo C.  2004.  Poly (ADP-ribose) polymerase inhibitors counteract diabetes-and hyposiz-induced retinal vascular endothelial growth factor overexpression. International Journal of Molecular Medicine 14: 55-64.

Pacher P, Vaslin A, Benko R, Mabley J, Liaudet L, Hasko G, Marton A, Batkai S, Kollai M, Szabo C.  2004.  A new, potent poly (ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advance aging. JPET 311:485-491.

Piconi L, Quagliaro L,  Da Ros R, Marini C, Giugliano D, Esposito K, Szabó C, Ceriello A. 2004. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost. 2(8):1453-9

Scott G, Kean R, Mikheeva T, Fabis M, Mabley J, Szabo C, Hooper D. 2004.  The therapeutic effects of PJ34 (N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCI), a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. JPET 310:1053-1061.

Sugawara R, Hikichi T, Kitaya N, Mori F, Nagaoka T, Yoshida A, Szabo C.  2004. Peroxynitrite decomposition catalyst, FP15, and poly (ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats. Curr Eye Res 29(1): 11-16

Szabo C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R, Chen M, Mabley J, Kollai M. 2004.  Angiotensin II-Mediated Endothelial Dysfunction: Role of poly (ADP-ribose) polymerase activation. Molecular Medicine 10: 1-3.

Szabo G, Andrasi T, Soos P, Mandera S, Heger U, Bahrle S, Cziraki A, Gries A, Vahl C, Hagle S, Szabo C. 2004. INO-1001 a novel poly (ADP-ribose) polymerase (PARP)-inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock 21(5):426-32.

Szabo G, Liaudet L, Hagl S, Szabo C.  2004.  Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovascular Research 61: 471-480.

Szabo G, Soos P, Bahrle S, Zsengeller Z, Flechtenmacher C, Hagl S, Szabo C.  2004. Role of poly (ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass. European Journal of Cardio-thoracic Surgery 25: 825-832

Virag L, Bai P, Bak I, Pacher P, Mabley J, Liaudet L, Bakondi E, Gergely P, Kollai M, Szabo C.  2004.  Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma. Med Sci Monit 10(3):BR77-83.

Woolley S, Farivar A, Naidu B, Salzman A, Szabo C, Thomas R, Fraga C, Mulligan M.  2004.  Role of Poly(ADP) ribose synthetase in lung ischemia-reperfusion injury. J Heart Lung Transplant 23:1290-6.

Xiao CY, Chin M, Zsengeller Z, Szabo C.  2004. Poly (ADP-ribose) polymerse contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor. JPET 310:498-504.

For a more comprehensive list of Inotek's PARP publications, please download the following PDF file:  PARP publications